PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30134793-7	2018	Treatment with metformin inhibited these variations and promoted the release of cytokine IL-10 with anti-inflammatory capability.	Metformin	15-24	interleukin 10	Mus musculus	89-94	
29899823-6	2018	Metformin treatment increased the number of lung CD8-effector-memory T and CD4+Foxp3+IL-10+ T cells in B16F10-transplanted mice.	Metformin	0-9	interleukin 10	Mus musculus	85-90	
30134793-8	2018	In vivo, metformin reduced the production of pro-inflammatory cytokines, osteoclastogenesis, and osteolysis, increasing IL-10 production.	Metformin	9-18	interleukin 10	Mus musculus	120-125	
28002460-0	2016	Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice.	Metformin	0-9	interleukin 10	Mus musculus	56-70	
28002460-11	2016	In correlation, the mRNA level of differentiation regulator including bmp4, bmpr2 and math1 were also increased in IL10KO mice supplemented with metformin, which likely explains the enhanced epithelial differentiation in IL10KO mice with metformin.	Metformin	145-154	interleukin 10	Mus musculus	115-119	
28002460-11	2016	In correlation, the mRNA level of differentiation regulator including bmp4, bmpr2 and math1 were also increased in IL10KO mice supplemented with metformin, which likely explains the enhanced epithelial differentiation in IL10KO mice with metformin.	Metformin	238-247	interleukin 10	Mus musculus	115-119	
31164166-12	2019	In addition, metformin reduced B cell differentiation into germinal center B cells, decreased the serum immunoglobulin G level, and maintained the balance between IL-10- and IL-17-producing B cells.	Metformin	13-22	interleukin 10	Mus musculus	163-179	
24009539-6	2013	On the other hand, the protein expressions of anti-inflammatory cytokines, IL-4 and IL-10, were enhanced or maintained by metformin.	Metformin	122-131	interleukin 10	Mus musculus	84-89	
31904843-8	2020	RESULTS: Metformin enhanced the immunomodulatory functions of Ad-MSCs including IDO, IL-10 and TGF-beta.	Metformin	9-18	interleukin 10	Mus musculus	85-90	
31904843-10	2020	STAT1 inhibition by siRNA strongly diminished IDO, IL-10, TGF-beta in metformin-treated Ad-MSCs.	Metformin	70-79	interleukin 10	Mus musculus	51-56	
31195189-7	2019	However, treatment with 200 mg of metformin was more effective in increasing neurotrophic (myelin basic protein and neural growth factor), angiogenic (vascular endothelial growth factor) and anti-inflammatory (inhibitor kappa B-alpha and interleukin 10) factors.	Metformin	34-43	interleukin 10	Mus musculus	238-252	
31268904-9	2019	RESULTS: Metformin improved Ox-LDL-impaired anti-inflammatory phenotype in raw264.7 macrophages as shown by up-regulated transcription of anti-inflammatory markers including interleukin 10 (0.76 +- 0.04 vs. 0.94 +- 0.01, P = 0.003) and Resistin-like molecule alpha (0.67 +- 0.08 vs. 1.78 +- 0.34, P = 0.030).	Metformin	9-18	interleukin 10	Mus musculus	174-188	
24716225-13	2014	Metformin significantly attenuated the severity of colitis in IL-10-/- mice, induced AMPK activity in intestinal epithelial cells, and inhibited the development of colitic cancer in mice.	Metformin	0-9	interleukin 10	Mus musculus	62-67	
34570348-7	2021	Moreover, metformin treatment significantly downregulated the expression of pro-inflammatory associated genes (iNOS, H2-Aa, and TNF-alpha) in the corpus callosum, whereas expression of anti-inflammatory markers (Arg1, Mrc1, and IL10) was not promoted, compared to CPZ mice.	Metformin	10-19	interleukin 10	Mus musculus	228-232	
30218721-9	2019	Moreover, metformin increased Ox-LDL-impaired IL-10 secretion, an important anti-foam cell cytokine in atherosclerosis.	Metformin	10-19	interleukin 10	Mus musculus	46-51